Search results
-
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
Hamermesh, Richard G.; Kucherlapati, Raju; Gordon, RachelCase HBS-810066-EEntrepreneurshipIn May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix...Starting at €8.20
-
Korea: After the 1997 Financial Crisis (Spanish version)
Alfaro, Laura; Di Tella, Rafael; Kim, ReneeCase HBS-708S17EconomicsExamines what happened to Korea after the 1997 financial crisis and the implementation of the IMF-mandated reforms imposed on Korea as conditionalities to the country's emergency loan package.Starting at €8.20
-
The Indego Africa Project (Spanish Version)
McGinn, Kathleen L.; Gordon, RachelCase HBS-914S10Dos abogados jóvenes que se encuentran y comienzan a construir el Proyecto África Indego, una asociación de ONG con cooperativas de mujeres en Ruanda. Indego conecta las cooperativas en el mercado minorista internacional de productos artesanales hechos a mano, ayuda a las cooperativas construyen su capacidad de negocio, y desarrolla y ofrece formación en el aula en la vida y habilidades de negocio para los miembros de la cooperativa. En el moment...Starting at €8.20
-
Storming into the U.S. Market (Spanish version)
Bartlett, Christopher A.; Gordon, Rachel; Lafkas, JohnCase HBS-918S10StrategyThe RoboTech case describes the challenges facing the CEO of a small, Singapore-based industrial robotics company that decides to diversify away from its core industrial robot business by leveraging its expertise into the medical-devices industry. It launches an innovative product (a specialized surgical robot) in an unfamiliar market segment (spinal surgery) and decides to enter the unfamiliar, distant U.S. healthcare market, which is characteri...Starting at €8.20
-
Intrapreneurship within FLG, Inc. (Spanish version)
Garvin, David A.; Gordon, RachelCase HBS-918S11EntrepreneurshipThis case follows Jenica Fletcher as she rebuilds her company's guitar strings division from the ground up. Convinced that she could turn the division around if given complete independence from corporate headquarters, Fletcher relocated the group, rebranded it as Malenti Strings, repositioned the guitar strings as high-performance products, and transformed Malenti into a fast-growing, profitable business. The case traces Fletcher's key steps in...Starting at €8.20
-
Controles de capital en Chile en la década de 1990 (B)
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-706S29EconomicsComplementa el caso (A).Starting at €5.74
-
Controles de capital en Chile en la década de 1990 (A)
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-706S32EconomicsEn 1991, Chile adoptó un marco de controles de capital se centró en la reducción de los flujos masivos de inversión extranjera que entra en el país ya que las tasas de interés internacionales se mantuvieron bajos. Las entradas de capital en peligro la capacidad del Banco Central para manejar el tipo de cambio dentro de una banda flotante, cuyo objetivo era el tiempo para bajar tasa de inflación de Chile a nivel internacional. Hasta la crisis fina...Starting at €8.20
-
To Float or Not to Float? (A) (Spanish version)
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S08EconomicsOn July 21, 2005 China revalued its decade-long quasi-fixed exchange rate of approximately 8.28 yuan per U.S. dollar by 2.1% to 8.11% and, at the same time, introduced a more market-based exchange rate system. Many analysts and economists were disappointed with what they considered too small a change and called for more flexibility in the U.S. dollar/yuan exchange rate. Modification to China's exchange rate regime had been eagerly anticipated and...Starting at €8.20
-
China: Flotar o no flotar (C) Esquel Group y el Renminbi chino
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S10EconomicsEn julio de 2005, China revaluó su moneda en un 2,1% y ajustar su régimen de tipo de cambio hacia un sistema más basado en el mercado. Esquel Group, una gestión familiar, textiles privadas firma especializada en camisas de algodón de alta calidad con su mayoría de base de producción se encuentra en China, estaba entre aquellas empresas que se enfrentan con el reto de hacer frente a la revaluación del yuan y la posibilidad de apreciación futura . ...Starting at €5.74
-
Embracing Globalization? (Spanish version)
Alfaro, LauraCase HBS-707S27EconomicsIn 2001, Brazil stands at a crossroads. The country seems to be emerging from decades of economic stagnation. The economic situation remains tenuous, however, Brazil's leaders must now chart a forward course. Most critically, they must decide whether Brazil's future rests with close links to the global economy.Starting at €8.20